Compare Cassava Sciences Inc (FLNA) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs DENTSPLY SIRONA Inc — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while DENTSPLY SIRONA Inc trades at $13.79 (market cap $2.68B). The key difference: DENTSPLY SIRONA Inc is far larger — about 50.4× Cassava Sciences Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | XRAY | |
|---|---|---|
Market Cap | $53.14M | $2.68B |
Sector | Health | Health |
52-Week High | $4.64 | $16.85 |
52-Week Low | $1.09 | $9.64 |
Enterprise Value | -$33.43M | $4.83B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
XRAY trades at $13.76, up 8.35% in 24 hours, with technical indicators showing a bullish trend. The stock has missed earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.36. Revenue declined to $3.68 billion in 2025, and the company reported a net loss of $598 million. Recent news highlights include distribution expansions and new AI-enabled product launches, while analyst sentiment remains mixed with a consensus price target of $13.33.
The outlook for XRAY is cautious due to persistent earnings misses and negative profitability, though technical momentum and strategic initiatives offer some upside potential. Key risks include margin pressure, high debt levels, and soft European demand. Investors should weigh the bullish technical signals against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
